Campbell & Co Investment Adviser’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Campbell & Co Investment Adviser’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-11,737	Closed	-$804K	–	1384
2024 Q2	$804K	Sell	11,737 -6,694	-36%	-$464K	0.07%	449
2024 Q1	$1.28M	Buy	+18,431	New	+$1.27M	0.11%	297
2023 Q2	–	Sell	-6,962	Closed	-$377K	–	1166
2023 Q1	$377K	Buy	6,962 +1,838	+36%	+$88.9K	0.07%	524
2022 Q4	$271K	Buy	+5,124	New	+$257K	0.06%	593
2022 Q2	–	Sell	-37,863	Closed	-$2.32M	–	964
2022 Q1	$2.32M	Buy	+37,863	New	+$1.97M	0.62%	5
2020 Q4	–	Sell	-8,355	Closed	-$214K	–	597
2020 Q3	$214K	Buy	+8,355	New	+$191K	0.16%	294

Other funds holding ITCI

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Campbell & Co Investment Adviser's ITCI Position: Q3 2024 in Review

Campbell & Co Investment Adviser sold out of Intra-Cellular Therapies Inc. (ITCI) in Q3 2024, closing a stake of 11,737 shares — an estimated $804K sold.

Campbell & Co Investment Adviser first reported a position in ITCI in Q3 2020 and held it in 6 quarters. The position peaked at $2.32M in Q1 2022. 355 funds tracked by Wall St. Rank hold ITCI as of Q3 2024.

Campbell & Co Investment Adviser reported no remaining Intra-Cellular Therapies Inc. position as of Q3 2024 after selling out during the quarter.
Campbell & Co Investment Adviser sold 11,737 Intra-Cellular Therapies Inc. shares in Q3 2024, an estimated $804K.
Campbell & Co Investment Adviser first reported a position in Intra-Cellular Therapies Inc. in Q3 2020 and held it in 6 quarters.
Campbell & Co Investment Adviser's Intra-Cellular Therapies Inc. position peaked at $2.32M in Q1 2022.
355 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q3 2024.

Based on Campbell & Co Investment Adviser's 13F filing for Q3 2024, filed 12 Nov 2024.